Compass Therapeutics reports $209M cash, tovecimig PFS/OS data on track Q1 2026; appoints CCO and CMO

Compass Therapeutics, Inc.

Cash and marketable securities estimated at $209M as of Dec 31, 2025; cash runway into 2028.
Analyses of PFS and OS in tovecimig Phase 2/3 BTC trial expected late Q1 2026; BLA preparation underway.
CTX-8371: third confirmed response in Hodgkin Lymphoma; expansions open in TNBC and NSCLC.
Appointed Arjun Prasad as CCO and Cynthia Sirard as CMO effective January 2026.
CTX-10726 Phase 1 initiation expected Q1 2026 with initial data in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.